Thiazolidine carboxamide derivatives as modulators of the prostaglandin f receptor

Abstract

The present invention is related to thiazolidine carboxamide derivatives of formula (II) for the treatment and/or prophylaxis of preterm labor, premature birth, dysmenorrhea and for stopping labor prior to cesarean delivery. G is selected from the group consisting of C 1 -C 6 -alkyl aryl, C 1 -C 6 -alkyl heteroaryl, C 1 -C 6 Alkyl cycloalkyl, C 1 -C 6 -alkyl heteroaryl, aryl, heteroaryl, C 3 -C 8 -cycloalkyl or -heterocycloalkyl, said cycloalkyl or aryl or hetetoaryl groups may be fused with cycloalkyl or aryl or heteroaryl groups. R 1 is selected from the group consisting of aryl, heteroaryl, C 3 -C 8 -cycloalkyl or -heterocyclo-alkyl, said (hetero)cycloalkyl or aryl or heteroaryl groups may be fused with (hetero)cycloalkyl or aryl or heteroaryl groups. R 2 is selected from the group consisting of H, carboxy, acyl, alkoxycarbonyl, aminocarbonyl, C 1 -C 5 -alkyl carboxy, C 1 -C 5 -alkyl acyl, C 1 -C 5 -alkyl alkoxycarbonyl, C 1 -C 5 -alkyl aminocarbonyl, C 1 -C 5 -alkyl acyloxy, C 1 -C 5 -alkyl acylamino, C 1 -C 5 -alkyl ureido, C 1 -C 5 alkyl amino, C 1 -C 5 -alkyl alkoxy, C 1 -C 5 -alkyl sulfanyl, C 1 -C 5 -alkyl sulfinyl, C 1 -C 5 -alkyl sulfonyl, C 1 -C 5 -alkyl sulfonylamino, C 1 -C 5 -alkyl sulfonyloxy, C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, aryl, heteroaryl, C 3 -C 8 -cycloalkyl, heterocycloalkyl, C 1 -C 6 -alkyl aryl, C 2 -C 6 -alkyl heteroaryl, C 1 -C 6 -alkyl cycloalkyl, C 1 -C 6 -alkyl heterocycloalkyl, C 2 -C 6 -alkenyl aryl, C 2 -C 6 -alkenyl heteroaryl, C 2 -C 6 -alkynyl aryl, or C 2 -C 6 -alkynyl heteroaryl.

1 . A compound, geometrical isomers of said compound, optically active forms of said compound, enantiomers of said compound, diastereomers of said compound, racemate forms of said compound, pharmaceutically acceptable salts of said compound and pharmaceutically active derivatives thereof, 
 wherein said compound is represented by formula II,                          G is selected from the group consisting of C 1 -C 6 -alkyl aryl, C 1 -C 6 -alkyl heteroaryl, C 1 -C 6 -alkyl cycloalkyl, C 1 -C 6 -alkyl heteroaryl, aryl, heteroaryl, C 3 -C 8 -cycloalkyl and C 3-8  heterocycloalkyl, wherein said cycloalkyl or aryl or heteroaryl groups are optionally fused with a cycloalkyl or aryl or heteroaryl group;    R 1  is selected from the group consisting of aryl, heteroaryl, C 3 -C 8 -cycloalkyl and a 3 to 8 membered heterocycloalkyl, wherein said (hetero)cycloalkyl or aryl or heteroaryl groups are optionally fused with a (hetero)cycloalkyl or aryl or heteroaryl group;    R 2  is selected from the group consisting of H, carboxy, acyl, alkoxycarbonyl, aminocarbonyl, C 1 -C 5 -alkyl carboxy, C 1 -C 5 -alkyl acyl, C 1 -C 5 -alkyl alkoxycarbonyl, C 1 -C 5 -alkyl aminocarbonyl, C 1 -C 5 -alkyl acyloxy, C 1 -C 5 -alkyl acylamino, C 1 -C 5 -alkyl ureido, C 1 -C 5 -alkyl amino, C 1 -C 5 -alkyl alkoxy, C 1 -C 5 -alkyl sulfanyl, C 1 -C 5 -alkyl sulfinyl, C 1 -C 5 -alkyl sulfonyl, C 1 -C 5 -alkyl sulfonylamino, C 1 -C 5 -alkyl sulfonyloxy, C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, aryl, heteroaryl, C 3 -C 8 -cycloalkyl, 3-8 membered heterocycloalkyl, C 1 -C 6 -alkyl aryl, C 2 -C 6 -alkyl heteroaryl, C 1 -C 6 -alkyl cycloalkyl, C 1 -C 6 -alkyl heterocycloalkyl, C 2 -C 6 -alkenyl aryl, C 2 -C 6 -alkenyl heteroaryl, C 2 -C 6 -alkynyl aryl, and C 2 -C 6 -alkynyl heteroaryl;    R 4  is selected from the group consisting of C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, and C 2 -C 6 -alkynyl; and    n is an integer from 0 to 2; or    R 2  and G optionally form a C 1 -C 8 -cycloalkyl ring.    
     
     
         2 . The compound, geometrical isomers of said compound, optically active forms of said compound, enantiomers of said compound, diastereomers of said compound, racemate forms of said compound, pharmaceutically acceptable salts of said compound and pharmaceutically active derivatives thereof according to  claim 1 , wherein G is an aryl group.  
     
     
         3 . A method of inhibiting a prostaglandin receptor comprising: 
 administering a composition comprising the compound, geometrical isomers of said compound, optically active forms of said compound, enantiomers of said compound, diastereomers of said compound, racemate forms of said compound, pharmaceutically acceptable salts of said compound and pharmaceutically active derivatives thereof as claimed in  claim 1  to a patient in need thereof.    
     
     
         4 . The method according to of  claim 3 , wherein said prostaglandin receptor is the prostaglandin F 2α  receptor.  
     
     
         5 . A compound, geometrical isomers of said compound, optically active forms of said compound, enantiomers of said compound, diastereomers of said compound, racemate forms of said compound, pharmaceutically acceptable salts of said compound and pharmaceutically active derivatives thereof 
 wherein said compound is represented by formula I,                          G′ is selected from the group consisting of aryl, heteroaryl, C 3 -C 8 -cycloalkyl and 3 to 8 membered heterocycloalkyl, wherein said cycloalkyl or aryl or heteroaryl groups are optionally fused with cycloalkyl or aryl or heteroaryl groups;    R 1  is selected from the group consisting of aryl, heteroaryl, C 1 -C 8 -cycloalkyl of and a 3 to 8 membered heterocycloalkyl, wherein said (hetero)cycloalkyl or aryl or heteroaryl groups are optionally fused with a (hetero)cycloalkyl or aryl or heteroaryl group;    R 2  is selected from the group consisting of H, carboxy, acyl, alkoxycarbonyl, aminocarbonyl, C 1 -C 5 -alkyl carboxy, C 1 -C 5 -alkyl acyl, C 1 -C 5 -alkyl alkoxycarbonyl, C 1 -C 5 alkyl aminocarbonyl, C 1 -C 5 -alkyl acyloxy, C 1 -C 5 -alkyl acylamino, C 1 -C 5 -alkyl ureido, C 1 -C 5 -alkyl amino, C 1 -C 5 -alkyl alkoxy, C 1 -C 5 -alkyl sulfanyl, C 1 -C 5 -alkyl sulfinyl, C 1 -C 5 -alkyl sulfonyl, C 1 -C 5 -alkyl sulfonylamino, C 1 -C 5 alkyl sulfonyloxy, C 1 -C 6 -alkyl. C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, aryl, heteroaryl, C 3 -C 8 -cycloalkyl, 3-8 membered heterocycloalkyl, C 1 -C 6 -alkyl aryl, C 2 -C 6 -alkyl heteroaryl, C 1 -C 6 -alkyl cycloalkyl, C 1 -C 6 -alkyl heterocycloalkyl, C 2 -C 6 -alkenyl aryl, C 2 -C 6 -alkenyl heteroaryl, C 2 -C 6 -alkynyl aryl, and C 2 -C 6 -alkynyl heteroaryl.    R 4  is selected from the group consisting of C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, and C 2 -C 6 -alkynyl; and    n is an integer from 0 to 2.    
     
     
         6 . The compound, geometrical isomers of said compound, optically active forms of said compound, enantiomers of said compound, diastereomers of said compound, racemate forms of said compound, pharmaceutically acceptable salts of said compound and pharmaceutically active derivatives thereof according to  claim 5 , 
 wherein said compound is represented by formula (Ia):                          R 3  is selected from the group consisting of C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, aryl, heteroaryl, C 3 -C 8 -cycloalkyl or heterocycloalkyl, C 1 -C 6 -alkyl aryl, C 1 -C 6 -alkyl heteroaryl, C 1 -C 3 -alkyl cycloalkyl, C 1 -C 3 -alkyl heterocycloalkyl, C 2-C   6 -alkenyl-aryl, C 2 -C 6  alkenyl-heteroaryl, C 2 -C 6 -alkynyl aryl, C 2 -C 6 -alkynyl heteroaryl carboxy, cyano, halogen, hydroxy, C 1 -C 6 -alkoxy, nitro, acylamino, ureido, sulfonylamino, sulfanyl, and sulfonyl; and    m is an integer from 0 to 3.    
     
     
         7 . The compound, geometrical isomers of said compound, optically active forms of said compound, enantiomers of said compound, diastereomers of said compound, racemate forms of said compound, pharmaceutically acceptable salts of said compound and pharmaceutically active derivatives thereof according to  claim 5  wherein R 1  is selected from the group consisting of an aryl and a heteroaryl group optionally substituted with at least one moiety selected from the group consisting of aryl, heteroaryl, halogen, alkoxy, sulfanyl, straight and branched C 1 -C 6 -alkyl.  
     
     
         8 . The compound, geometrical isomers of said compound, optically active forms of said compound, enantiomers of said compound, diastereomers of said compound, racemate forms of said compound, pharmaceutically acceptable salts of said compound and pharmaceutically active derivatives thereof according to  claim 5 , 
 wherein R 2  is C 1 -C 3 -alkyl-A-R 5 ;    A is O or a moiety of the formula N-B-R 6 ;    B is selected from the group consisting of a bond, an amino acid residue, (C═O), (C═O)—O, (C═O)—NR 7 , and SO 2 ;    R 5 , R 6  and R 7  are independently selected from the group consisting of H, C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, aryl, heteroaryl, C 3 -C 8 -cycloalkyl C 3 -C 8 -heterocycloalkyl, C 1 -C 6 -alkyl aryl, C 1 -C 6 -alkyl heteroaryl, C 1 -C 6 -alkyl cycloalkyl, C 1 -C 6 -alkyl heterocycloalkyl, C 2 -C 6 -alkenyl aryl C 2 -C 6 -alkenyl heteroaryl, C 2 -C 6 -alkynyl aryl and C 2 -C 6 -alkynyl heteroaryl; or    R 6  and R 7 , or R 5  and B—R 6  together with the respective nitrogen atoms to which they are attached, optionally form a substituted or unsubstituted heterocycloalkyl ring.    
     
     
         9 . The compound, geometrical isomers of said compound, optically active forms of said compound, enantiomers of said compound, diastereomers of said compound, racemate forms of said compound, pharmaceutically acceptable salts of said compound and pharmaceutically active derivatives thereof according to  claim 8 , 
 wherein R 2  is C 1 -C 3 -alkyl-A-R 5 ;    A is O and    R 5  is H, or    A is N—B—R 6  wherein B is a bond, and R 5  and R 6  are independently selected from the group consisting of C 1 -C 3 -alkyl, C 1 -C 3 -alkyl hydroxy, C 1 -C 3 -alkyl carboxy, C 1 -C 3 -alkyl aminocarbonyl, C 1 -C 3 -alkyl alkoxycarbonyl, C 1 -C 3 -alkyl aryl, C 1 -C 3 -alkyl heteroaryl, C 1 -C 3 -alkyl cycloalkyl, and C 1 -C 3 -alkyl heterocycloalkyl.    
     
     
         10 . The compound geometrical isomers of said compound, optically active forms of said compound, enantiomers of said compound, diastereomers of said compound, racemate forms of said compound, pharmaceutically acceptable salts of said compound and pharmaceutically active derivatives thereof according to  claim 7 , wherein R 2  is selected from the group consisting of phenyl, pyrid-2-yl, pyrid-3-yl, and pyrid-4-yl.  
     
     
         11 . The compound, geometrical isomers of said compound, optically active forms of said compound, enantiomers of said compound, diastereomers of said compound, racemate forms of said compound, pharmaceutically acceptable salts of said compound and pharmaceutically active derivatives thereof according to  claim 5 , 
 wherein R 1  is a phenyl substituted with a group selected from the group consisting of a straight C 1 -C 5 -alkyl, branched C 1 -C 5 -alkyl, and C 1 -C 5 -aryl;    R 2  is selected from the group consisting of C 1 -C 3 -alkyl-A-R 5  
 wherein A is O and R 5  is H, or  
 A is N-B-R 6  wherein B is a bond and R 5  and R 6  are independently selected from the group consisting of C 1 -C 3 -alkyl, C 1 -C 3 -alkyl aryl, C 1 -C 3 -alkyl heteroaryl, and C 1 -C 3 -alkyl-hydroxy.  
   
     
     
         12 . The compound, geometrical isomers of said compound, optically active forms of said compound, enantiomers of said compound, diastereomers of said compound, racemate forms of said compound, pharmaceutically acceptable salts of said compound and pharmaceutically active derivatives thereof according to  claim 11   wherein R 1  is a biphenyl or a tert-butyl phenyl group,    R 2  is C 1 -C 3 -alkyl-A-R 5 , 
 wherein A is O and  
 R 5  is H, or  
 A is N-B-R 6 ,  
 R 5  and R 6  are independently selected from the group consisting of C 1 -C 3 -alkyl, C 1 -C 3 -alkyl aryl, C 1 -C 3 -alkyl heteroaryl, and C 1 -C 3 -alkyl hydroxy,  
 B is a bond,  
 R 3  is fluorine,  
 m is 0, 1, or 2, and  
 n is 0.  
   
     
     
         13 . The compound, geometrical isomers of said compound, optically active forms of said compound, enantiomers of said compound, diastereomers of said compound, racemate forms of said compound, pharmaceutically acceptable salts of said compound and pharmaceutically active derivatives thereof according to  claim 1  selected from the group consisting of 
 (2R)-3-([1,1′-biphenyl]-4-ylsulfonyl)-N-[(1S)-3-hydroxy-1-phenylpropyl]-1,3-thiazolidine-2-carboxamide;    (2R)-3-([1,1′-biphenyl]-4-ylsulfonyl)-N-[(R)-phenyl(2-pyridinyl)methyl]-1,3-thiazolidine-2-carboxamide;    (2R)-3-[(4-tert-butylphenyl)sulfonyl]-N-[(1S)-3-hydroxy-1-phenylpropyl]-1,3-thiazolidine-2-carboxamide;    (2R)-N-[(1S)-3-hydroxy-1-phenylpropyl]-3-[(4-tert-pentylphenyl)sulfonyl]-1,3-thiazolidine-2-carboxamide;    (2S)-2-({[3-([1,1′-biphenyl]-4-ylsulfonyl)-1,3-thiazolidin-2-yl]carbonyl}amino)-3-phenylpropanoic acid;    (2S)-2-[({3-[(5-chloro-3-methyl-1-benzothien-2-yl)sulfonyl]-1,3-thiazolidin-2-yl}carbonyl)amino]-3-phenylpropanoic acid;    (2S)-3-([1,1′-biphenyl]-4-ylsulfonyl)-N-((1S)-3-{methyl[2-(2-pyridinyl)ethyl]amino}-1-phenylpropyl)-1,3-thiazolidine-2-carboxamide;    (2S)-3-([1,1′-biphenyl]-4-ylsulfonyl)-N-[(1S)-1-phenyl-2-propenyl]-1,3-thiazolidine-2-carboxamide;    (2S)-3-([1,1′-biphenyl]-4-ylsulfonyl)-N-[(1S)-3-(diethylamino)-1-phenylpropyl]-1,3-thiazolidine-2-carboxamide;    (2S)-3-([1,1′-biphenyl]-4-ylsulfonyl)-N-[(1S)-3-hydroxy-1-phenylpropyl]-1,3-thiazolidine-2-carboxamide;    (2S)-3-([1,1′-biphenyl]-4-ylsulfonyl)-N-[(R)-phenyl(2-pyridinyl)methyl]-1,3-thiazolidine-2-carboxamide;    (2S)-3-([1,1′-biphenyl]-4-ylsulfonyl)-N-{(1S)-3-[(2-furylmethyl)(methyl)amino]-1-phenylpropyl}-1,3-thiazolidine-2-carboxamide;    (2S)-3-([1,1′-biphenyl]-4-ylsulfonyl)-N-{(1S)-3-[(2-hydroxyethyl)(methyl)amino]-1-phenylpropyl}-1,3-thiazolidine-2-carboxamide;    (2S)-3-([1,1′-biphenyl]-4-ylsulfonyl)-N-{(1S)-3-[2-(2-hydroxyethyl)-1-piperidinyl]-1-phenylpropyl}-1,3-thiazolidine-2-carboxamide;    (2S)-3-([1,1′-biphenyl]-4-ylsulfonyl)-N-{(1S)-3-[4-(2-methoxyphenyl)-1-piperazinyl]-1-phenylpropyl}-1,3-thiazolidine-2-carboxamide;    (2S)-3-[(4-tert-butylphenyl)sulfonyl]-N-[(1S)-3-hydroxy-1-phenylpropyl]-1,3-thiazolidine-2-carboxamide;    (2S)-3-phenyl-2-{[(3-{[5-(2-pyridinyl)-2-thienyl]sulfonyl)-1,3-thiazolidin-2-yl)carbonyl]amino}propanoic acid;    (2S)-N-[(1S)-3-hydroxy-1-phenylpropyl]-3-[(4-tert-pentylphenyl)sulfonyl]-1,3-thiazolidine-2-carboxamide;    (2S)-N-{(1S)-3-[benzyl(methyl)amino]-1-phenylpropyl)-3-([1,1′-biphenyl]-4-ylsulfonyl)-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-(1-phenyl-3-{[(2S)-tetrahydro-2-furanylmethyl]-amino}propyl)-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-(1-phenyl-3-{[2-(1-piperidinyl)ethyl]amino}-propyl)-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-(1-phenyl-3-{[2-(2-pyridinyl)ethyl]amino}propyl)-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-(1-phenyl-3-{[2-(3-pyridinyl)ethyl]amino}propyl)-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-(1-phenylpropyl)-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-(2,3-difluorobenzyl)-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-(2,4-difluorobenzyl)-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-(2,5-difluorobenzyl)-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-(2,6-difluorobenzyl)-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-(2-chloro-4-fluorobenzyl)-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-(2-fluorobenzyl)-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-(2-furylmethyl)-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-(2-methoxybenzyl)-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-(2-methylbenzyl)-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-(2-phenylpropyl)-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-(2-thienylmethyl)-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-(3,4-difluorobenzyl)-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-(3-{[(2R)-2-hydroxy-2-phenylethyl]amino}-1-phenylpropyl)-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-(3-{[(2S)-2-hydroxypropyl]amino}-1-phenylpropyl)-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-(3-{[(5-methyl-2-furyl)methyl]amino}-1-phenylpropyl)-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-(3-{[2-(1H-indol-3-yl)ethyl]amino}-1-phenylpropyl)-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-(3-{[2-(1-methyl-2-pyrrolidinyl)ethyl]amino}-1-phenylpropyl)-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-(3-{[2-(4-morpholinyl)ethyl]amino}-1-phenylpropyl)-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-(3-{[2-(dimethylamino)ethyl]amino}-1-phenylpropyl)-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-(3-{[3-(2-oxo-1-pyrrolidinyl)propyl]amino}-1-phenylpropyl)-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-(3-{[3-(4-morpholinyl)propyl]amino}-1-phenylpropyl)-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-(3-{methyl[(1R)-1-phenylethyl]amino}-1-phenylpropyl)-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-(3-{methyl[(1S)-1-phenylethyl]amino}-1-phenylpropyl)-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-(3-{methyl[2-(2-pyridinyl)ethyl]amino}-1-phenylpropyl)-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-(3-chloro-4-fluorobenzyl)-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-(3-fluorobenzyl)-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-(3-hydroxy-1-phenylpropyl)-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-(3-methylbenzyl)-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-(3-phenoxy-1-phenylpropyl)-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-(3-pyridinylmethyl)-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-(4-fluorobenzyl)-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-(4-phenoxybenzyl)-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-[(1,5-dimethyl-1H-pyrrol-2-yl)methyl]-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-[(1-oxido-2-pyridinyl)methyl]-1,3-thiazolidine-2-carboxamide 1-oxide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-[(1R)-2-hydroxy-1-phenylethyl]-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-[(1R)-3-hydroxy-1-phenylpropyl]-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-[(1S)-1-phenylethyl]-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-[(1S)-3-hydroxy-1-phenylpropyl]-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-[(R)-{6-[2-(dimethylamino)ethoxy]-2-pyridinyl}-(phenyl)methyl]-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-[(R)-phenyl(2-pyridinyl)methyl]-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-[(S)-phenyl(2-pyridinyl)methyl]-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-[1-(2,6-difluorophenyl)-3-hydroxypropyl]-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-[1-(2-chlorophenyl)-3-hydroxypropyl]-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-[1-(2-furyl)-3-hydroxypropyl]-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-[1-(3,4-dichlorophenyl)-3-hydroxypropyl]-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-[1-(3-chlorophenyl)-3-hydroxypropyl]-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-[1-(3-furyl)-3-hydroxypropyl]-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-[1-(4-chlorophenyl)-3-hydroxypropyl]-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-[1-(4-chlorophenyl)ethyl]-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-[1-(4-fluorophenyl)-3-hydroxypropyl]-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-[1-(4-fluorophenyl)ethyl]-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-[1-phenyl-2-(1-pyrrolidinyl)ethyl]-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-[1-phenyl-3-({[(1S,2R,3R,5S)-2,6,6-trimethyl-bicyclo[3.1.1]hept-3-yl]methyl}amino)propyl]-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-[1-phenyl-3-(1-piperazinyl)propyl]-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-[1-phenyl-3-(1-piperidinyl)propyl]-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-[1-phenyl-3-(1-pyrrolidinyl)propyl]-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-[2-(4-morpholinyl)-1-phenylethyl]-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-[2-(dimethylamino)-1-phenylethyl]-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-[3-((3R)-3-(hydroxymethyl)-3,4-dihydro-2(1H)-isoquinolinyl)-1-phenylpropyl]-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-[3-((3S)-3-(hydroxymethyl)-3,4-dihydro-2(1H)-isoquinolinyl)-1-phenylpropyl]-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-[3-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-1-phenylpropyl]-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-[3-(2,5-dihydro-1H-pyrrol-1-yl)-1-phenylpropyl]-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-[3-(3,5-dimethyl-1-piperidinyl)-1-phenylpropyl]-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-[3-(3,6-dihydro-1 (2H)-pyridinyl)-1-phenylpropyl]-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-[3-(3-hydroxy-1-piperidinyl)-1-phenylpropyl]-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-[3-(3-hydroxy-1-pyrrolidinyl)-1-phenylpropyl]-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-[3-(3-methyl-1-piperidinyl)-1-phenylpropyl]-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-[3-(4-hydroxy-1-piperidinyl)-1-phenylpropyl]-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-[3-(4-hydroxy-4-phenyl-1-piperidinyl)-1-phenylpropyl]-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-[3-(4-methyl-1-piperazinyl)-1-phenylpropyl]-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-[3-(4-morpholinyl)-1-phenylpropyl]-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-[3-(diethylamino)-1-phenylpropyl]-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-[3-(dimethylamino)-1-phenylpropyl]-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-[3-hydroxy-1-(2-methoxyphenyl)propyl]-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-[3-hydroxy-1-(2-methylphenyl)propyl]-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-[3-hydroxy-1-(3-methoxyphenyl)propyl]-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-[3-hydroxy-1-(3-pyridinyl)propyl]-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-[3-hydroxy-1-(4-methoxyphenyl)propyl]-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-[3-hydroxy-1-(4-methylphenyl)propyl]-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-[phenyl(2-pyridinyl)methyl]-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-{1-phenyl-3-[(2-phenylethyl)amino]propyl}-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-{1-phenyl-3-[(2-phenylpropyl)amino]propyl}-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-{1-phenyl-3-[(2-pyridinylmethyl)amino]propyl}-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-{1-phenyl-3-[(3-pyridinylmethyl)amino]propyl}-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-{1-phenyl-3-[(tetrahydro-2-furanylmethyl)amino]-propyl}-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-{1-phenyl-3-[4-(1-pyrrolidinyl)-1-piperidinyl]-propyl}-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-{3-[(2-furylmethyl)(methyl)amino]-1-phenyl-propyl}-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-{3-[(2-furylmethyl)amino]-1-phenylpropyl}-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-{3-[(2-hydroxy-2-phenylethyl)(methyl)amino]-1-phenylpropyl}-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-{3-[(2-hydroxy-2-phenylethyl)amino]-1-phenyl-propyl}-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-{3-[(2-hydroxycyolohexyl)amino]-1-phenylpropyl}-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-{3-[(2-hydroxyethyl)(methyl)amino]-1-phenylpropyl}-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-{3-[(2-hydroxyethyl)amino]-1-phenylpropyl}-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-{3-[(2-hydroxypropyl)amino]-1-phenylpropyl}-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-{3-[(2R)-2-(hydroxymethyl)pyrrolidinyl]-1-phenylpropyl}-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-{3-[(2R)-2-(methoxymethyl)pyrrolidinyl]-1-phenylpropyl}-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-{3-[(2S)-2-(methoxymethyl)pyrrolidinyl]-1-phenylpropyl}-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-{3-[(3,5-difluorobenzyl)amino]-1-phenylpropyl}-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-{3-[(3-hydroxy-3-phenylpropyl)(methyl)amino]-1-phenylpropyl}-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-{3-[(3-hydroxypropyl)amino]-1-phenylpropyl}-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-{3-[(3R)-3-hydroxlypyrrolidinyl]-1-phenylpropyl}-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-{3-[(4-fluorobenzyl)amino]-1-phenylpropyl}-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-{3-[[3-(dimethylamino)propyl](methyl)amino]-1-phenylpropyl}-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-{3-[2-(hydroxymethyl)-1-piperidinyl]-1-phenylpropyl}-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-{3-[3-(hydroxymethyl)-1-piperidinyl]-1-phenylpropyl}-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-{3-[4-(2-hydroxyethyl)-1-piperidinyl]-1-phenylpropyl)}-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-{3-[4-(hydroxymethyl)-1-piperidinyl]-1-phenylpropyl}-1,3-thiazolidine-2-carboxamide;    3-([1,1′-biphenyl]-4-ylsulfonyl)-N-{3-[methyl(2-phenylethyl)amino]-1-phenylpropyl}-1,3-thiazolidine-2-carboxamide;    3-[(3′,4′-dichloro[1,1′-biphenyl]-4-yl)sulfonyl]-N-[1-(2-furyl)-3-hydroxypropyl]-1,3-thiazolidine-2-carboxamide;    3-[(4′-chloro[1,1′-biphenyl]-4-yl)sulfonyl]-N-[1-(2-furyl)-3-hydroxypropyl]-1,3-thiazolidine-2-carboxamide;    3-[(4-chlorophenyl)sulfonyl]-N-(2-pyridinylmethyl)-1,3-thiazolidine-2-carboxamide;    3-[(4-chlorophenyl)sulfonyl]-N-{4-[({[(2-ethylhexyl)amino]carbonyl}amino)methyl]benzyl}-1,3-thiazolidine-2-carboxamide;    3-[(4-chlorophenyl)sulfonyl]-N-{4-[({[(2-phenylethyl)amino]carbonyl}amino)methyl]benzyl}-1,3-thiazolidine-2-carboxamide;    3-[(4-chlorophenyl)sulfonyl]-N-{4-[({[(4-methylbenzyl)amino]carbonyl}amino)methyl]benzyl}-1,3-thiazolidine-2-carboxamide;    3-[(4′-fluoro[1,1′-biphenyl]-4-yl)sulfonyl]-N-[1-(2-furyl)-3-hydroxypropyl]-1,3-thiazolidine-2-carboxamide;    3-[(4-iodophenyl)sulfonyl]-N-{4-[({[(4-methylbenzyl)amino]carbonyl}amino)methyl]benzyl}-1,3-thiazolidine-2-carboxamide;    3-[(4-tert-butylphenyl)sulfonyl]-N-(1,2-diphenylethyl)-1,3-thiazolidine-2-carboxamide;    3-[(4-tert-butylphenyl)sulfonyl]-N-(1-phenylethyl)-1,3-thiazolidine-2-carboxamide;    3-[(4-tert-butylphenyl)sulfonyl]-N-(2,3-dihydro-1H-inden-1-yl)-1,3-thiazolidine-2-carboxamide;    3-[(4-tert-butylphenyl)sulfonyl]-N-(2-furylmethyl)-1,3-thiazolidine-2-carboxamide;    3-[(4-tert-butylphenyl)sulfonyl]-N-(2-phenylpropyl)-1,3-thiazolidine-2-carboxamide;    3-[(4-tert-butylphenyl)sulfonyl]-N-(3-hydroxy-1-phenylpropyl)-1,3-thiazolidine-2-carboxamide;    3-[(4-tert-butylphenyl)sulfonyl]-N-(3-pyridinylmethyl)-1,3-thiazolidine-2-carboxamide;    3-[(4-tert-butylphenyl)sulfonyl]-N-[2-(1H-indol-3-yl)-1-methylethyl]-1,3-thiazolidine-2-carboxamide;    3-[(4-tert-butylphenyl)sulfonyl]-N-{[1-(4-chlorophenyl)cyclopropyl]methyl}-1,3-thiazolidine-2-carboxamide;    3-[(4-tert-butylphenyl)sulfonyl]-N-{4-[3-(dimethylamino)propoxy]benzyl}-1,3-thiazolidine-2-carboxamide;    3-{[5-(3-isoxazolyl)-2-thienyl]sulfonyl}-N-{4-[({[(2-phenylethyl)amino]carbonyl}-amino)methyl]benzyl}-1,3-thiazolidine-2-carboxamide;    ethyl {4-[(3S)-3-({[(2S)-3-([1,1′-biphenyl]-4-ylsulfonyl)-1,3-thiazolidin-2-yl]-carbonyl}amino)-3-phenylpropyl]-1-piperazinyl}acetate;    methyl [[(3S)-3-({[(2S)-3-([1,1′-biphenyl]-4-ylsulfonyl)-1,3-thiazolidin-2-yl]-carbonyl}amino)-3-phenylpropyl](methyl)amino]acetate;    N-(2,2-diphenylethyl)-3-(8-quinolinylsulfonyl)-1,3-thiazolidine-2-carboxamide;    N-(2-aminobenzyl)-3-([1,1′-biphenyl]-4-ylsulfonyl)-1,3-thiazolidine-2-carboxamide;    N-(3-{[2-(acetylamino)ethyl]amino)-1-phenylpropyl)-3-([1,1′-biphenyl]-4-ylsulfonyl)-1,3-thiazolidine-2-carboxamide;    N-(3-amino-1-phenylpropyl)-3-([1,1′-biphenyl]-4-ylsulfonyl)-1,3-thiazolidine-2-carboxamide;    N-(3-aminobenzyl)-3-[(4-tert-butylphenyl)sulfonyl]-1,3-thiazolidine-2-carboxamide;    N-(3-hydroxy-1-phenylpropyl)-3-[(4-phenoxyphenyl)sulfonyl]-1,3-thiazolidine-2-carboxamide;    N-(4-aminobenzyl)-3-[(4-tert-butylphenyl)sulfonyl]-1,3-thiazolidine-2-carboxamide;    N-[(1R)-1-benzyl-2-hydroxyethyl]-3-([1,1′-biphenyl]-4-ylsulfonyl)-1,3-thiazolidine-2-carboxamide;    N-[(6-amino-3-pyridinyl)methyl]-3-[(4-tert-butylphenyl)sulfonyl]-1,3-thiazolidine-2-carboxamide;    N-[1-(1,3-benzodioxol-5-yl)-3-hydroxypropyl]-3-([1,1′-biphenyl]-4-ylsulfonyl)-1,3-thiazolidine-2-carboxamide;    N-[1-(1-benzofuran-2-yl)-3-hydroxypropyl]-3-([1,1′-biphenyl]-4-ylsulfonyl)-1,3-thiazolidine-2-carboxamide;    N-[1-(2-furyl)-3-hydroxypropyl]-3-[(2′-methyl[1,1′-biphenyl]-4-yl)sulfonyl]-1,3-thiazolidine-2-carboxamide;    N-[1-(2-furyl)-3-hydroxypropyl]-3-[(4′-methoxy[1,1′-biphenyl]-4-yl)sulfonyl]-1,3-thiazolidine-2-carboxamide;    N-[1-(2-furyl)-3-hydroxypropyl]-3-[(4′-methyl[1,1′-biphenyl]-4-yl)sulfonyl]-1,3-thiazolidine-2-carboxamide;    N-[3-(1-azepanyl)-1-phenylpropyl]-3-([1,1′-biphenyl]-4-ylsulfonyl)-1,3-thiazolidine-2-carboxamide;    N-[3-(4-acetyl-1-piperazinyl)-1-phenylpropyl]-3-([1,1′-biphenyl]-4-ylsulfonyl)-1,3-thiazolidine-2-carboxamide;    N-[3-(4-benzyl-4-hydroxy-1-piperidinyl)-1-phenylpropyl]-3-([1,1′-biphenyl]-4-ylsulfonyl)-1,3-thiazolidine-2-carboxamide;    N-[3-(acetylamino)-1-phenylpropyl]-3-([1,1′-biphenyl)-4-ylsulfonyl)-1,3-thiazolidine-2-carboxamide;    N-[3-(benzylamino)-1-phenylpropyl]-3-([1,1′-biphenyl]-4-ylsulfonyl)-1,3-thiazolidine-2-carboxamide;    N-[4-({[(hexylamino)carbonyl]amino}methyl)benzyl]-3-(phenylsulfonyl)-1,3-thiazolidine-2-carboxamide;    N-[4-({[(hexylamino)carbonyl]amino}methyl)benzyl]-3-{[5-(3-isoxazolyl)-2-thienyl]sulfonyl)}-1,3-thiazolidine-2-carboxamide;    N-{3-[(1-adamantylmethyl)amino]-1-phenylpropyl}-3-([1,1′-biphenyl]-4-ylsulfonyl)-1,3-thiazolidine-2-carboxamide;    N-{3-[(2R)-2-(anilinomethyl)pyrrolidinyl]-1-phenylpropyl}-3-([1,1′-biphenyl]-4-ylsulfonyl)-1,3-thiazolidine-2-carboxamide;    N-{3-[(2S)-2-(anilinomethyl)pyrrolidinyl]-1-phenylpropyl}-3-([1,1′-biphenyl]-4-ylsulfonyl)-1,3-thiazolidine-2-carboxamide;    N-{3-[benzyl(2-hydroxyethyl)amino]-1-phenylpropyl}-3-([1,1′-biphenyl]-4-ylsulfonyl)-1,3-thiazolidine-2-carboxamide;    N-{3-[benzyl(methyl)amino]-1-phenylpropyl}-3-([1,1′-biphenyl]-4-ylsulfonyl)-1,3-thiazolidine-2-carboxamide;    N-{4-[({[(2-ethylhexyl)amino]carbonyl}amino)methyl]benzyl}-3-[(4-iodophenyl)-sulfonyl]-1,3-thiazolidine-2-carboxamide;    N-benzhydryl-3-([1,1′-biphenyl]-4-ylsulfonyl)-1,3-thiazolidine-2-carboxamide;    N-benzhydryl-3-(8-quinolinylsulfonyl)-1,3-thiazolidine-2-carboxamide;    N-benzyl {3-[(4-tert-butylphenyl)sulfonyl]-1,3-thiazolidin-2-yl}methanamine;    N-benzyl-3-([1,1′-biphenyl]-4-ylsulfonyl)-1,3-thiazolidine-2-carboxamide;    N-benzyl-3-[(4-tert-butylphenyl)sulfonyl]-1,3-thiazolidine-2-carboxamide;    tert-butyl 3-{[({3-[(4-tert-butylphenyl)sulfonyl]-1,3-thiazolidin-2-yl}carbonyl)amino]methyl}phenylcarbamate;    tert-butyl 5-{2-[({3-[(4-tert-butylphenyl)sulfonyl]-1,3-thiazolidin-2-yl}carbonyl)amino]ethyl}-2-pyridinylcarbamate;    (3S)-3-({[(2S)-3-(biphenyl-4-ylsulfonyl)-1,3-thiazolidin-2-yl]carbonyl}amino)-3-(2,6-difluorophenyl)propyl L-valinate;    (3S)-3-(2,6-difluorophenyl)-3-[({(2S)-3-[(2′-fluorobiphenyl-4-yl)sulfonyl]-1,3-thiazolidin-2-yl}carbonyl)amino]propyl L-valinate;    (3S)-3-({[(2S)-3-(biphenyl-4-ylsulfonyl)-1,3-thiazolidin-2-yl]carbonyl}amino)-3-phenylpropyl L-valinate;    (3S)-3-[({(2S)-3-[(2′-fluorobiphenyl-4-yl)sulfonyl]-1,3-thiazolidin-2-yl)carbonyl}amino]-3-phenylpropyl L-valinate;    (2S)-3-(biphenyl-4-ylsulfonyl)-N-[(1S)-1-(4-fluorophenyl)-3-hydroxypropyl]-1,3-thiazolidine-2-carboxamide;    3-({[(3S)-3-({[3-(biphenyl-4-ylsulfonyl)-1,3-thiazolidin-2-yl]carbonyl}amino)-3-phenylpropyl]amino}sulfonyl)benzoic acid;    (2S)-N-[(1S)-1-(2,6-difluorophenyl)-3-hydroxypropyl]-3-[(2′-fluorobiphenyl-4-yl)sulfonyl]-1,3-thiazolidine-2-carboxamide;    (2S)-3-[(2′-fluorobiphenyl-4-yl)sulfonyl]-N-[(R)-phenyl(pyridin-2-yl)methyl]-1,3-thiazolidine-2-carboxamide;    (2S)-3-[(2′-fluorobiphenyl-4-yl)sulfonyl]-N-[(S)-(1-methylpiperidin-4-yl)(phenyl)methyl]-1,3-thiazolidine-2-carboxamide;    3-(biphenyl-4-ylsulfonyl)-N-[(2-chloropyridin-4-yl)(phenyl)methyl]-1,3-thiazolidine-2-carboxamide;    3-(biphenyl-4-ylsulfonyl)-N-[(6-hydroxypyridin-3-yl)(phenyl)methyl]-1,3-thiazolidine-2-carboxamide;    (2S)-3-[(2′-fluorobiphenyl-4-yl)sulfonyl]-N-[(R)-phenyl(pyridin-4-yl)methyl]-1,3-thiazolidine-2-carboxamide;    (2S)-3-[(4-iodophenyl)sulfonyl]-N-[(R)-phenyl(pyridin-2-yl)methyl]-1,3-thiazolidine-2-carboxamide;    3-(biphenyl-4-ylsulfonyl)-N-[[5-(2-hydroxyethyl)-1,2,4-oxadiazol-3-yl](phenyl)methyl]-1,3-thiazolidine-2-carboxamide;    methyl 2-methyl-2-(4-{[2-({[(R)-phenyl(pyridin-2-yl)methyl]amino}carbonyl)-1,3-thiazolidin-3-yl]sulfonyl}phenyl)propanoate;    3-(biphenyl-4-ylsulfonyl)-N-[(6-chloropyridin-3-yl)(phenyl)methyl]-1,3-thiazolidine-2-carboxamide;    (2S)-3-(biphenyl-4-ylsulfonyl)-N-{(1S)-3-[methyl(methylsulfonyl)amino]-1-phenylpropyl)-1,3-thiazolidine-2-carboxamide;    3-{[4-(2-fluoro-1,1-dimethylethyl)phenyl]sulfonyl}-N-[(R)-pheny](pyridin-2-yl)methyl]-1,3-thiazolidine-2-carboxamide;    (2S)-3-[(4-bromophenyl)sulfonyl]-N-[(R)-phenyl(pyridin-2-yl)methyl]-1,3-thiazolidine-2-carboxamide;    (3S)-3-phenyl-3-[({(2S)-3-[(4-vinylphenyl)sulfonyl]-1,3-thiazolidin-2-yl}carbonyl)amino]propyl L-valinate;    3-(biphenyl-4-ylsulfonyl)-N-[{5-[2-(dimethylamino)ethoxy]pyridin-2-yl}(phenyl)methyl]-1,3-thiazolidine-2-carboxamide;    3-(biphenyl-4-ylsulfonyl)-N-[[6-(dimethylamino)pyridin-3-yl](phenyl)methyl]-1,3-thiazolidine-2-carboxamide; and    3-(biphenyl-4-ylsulfonyl)-N-[phenyl(1-L-valylpiperidin-4-yl)methyl]-1,3-thiazolidine2-carboxamide.    
     
     
         14 . The compound, geometrical isomers of said compound, optically active forms of said compound as enantiomers, diastereomers and racemate forms, pharmaceutically acceptable salts and pharmaceutically active derivatives thereof according to  claim 5 , wherein the compound, geometrical isomers of said compound, optically active forms of said compound as enantiomers, diastereomers and racemate forms, pharmaceutically acceptable salts and pharmaceutically active derivatives thereof is capable of being utilized as a medicament.  
     
     
         15 . A pharmaceutical composition comprising at least one compound according to  claim 5  and a pharmaceutically acceptable carrier, diluent or excipient thereof.  
     
     
         16 . A method of preparing the compound of formula (I) a according to  claim 5 , comprising: 
 deprotecting a first compound represented by formula V in the presence of a base and a second compound represented by formula VI to obtain the compound represented by formula I                          wherein PG is a protecting group selected from Boc, Fmoc and Cbz.    
     
     
         17 . A method of preparing the compound represented by formula I according to  claim 5 , comprising: 
 peptide coupling a first compound represented by formula VIII with a second compound represented by formula IV to obtain the compound represented by formula I.                          
     
     
         18 . A compound of the formula Va,  
       
         
           
           
               
               
           
         
         wherein PG is H,  
         R 2  is selected from the group consisting of H, carboxy, acyl, alkoxycarbonyl, aminocarbonyl, C 1 -C 5 -alkyl carboxy, C 1 -C 5 -alkyl acyl, C 1 -C 5 -alkyl alkoxycarbonyl, C 1 -C 5 -alkyl aminocarbonyl, C 1 -C 5 -alkyl acyloxy, C 1 -C 5 -alkyl acylamino, C 1 -C 5 -alkyl ureido, C 1 -C 5 -alkyl amino, C 1 -C 5 -alkyl alkoxy, C 1 -C 5 -alkyl sulfanyl, C 1 -C 5 -alkyl sulfinyl, C 1 -C 5 -alkyl sulfonyl, C 1-5 -alkyl sulfonylamino, C 1- C 5 -alkyl sulfonyloxy, C 1- C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, aryl, heteroaryl, C 3 -C 8 -cycloalkyl, 3-8 membered heterocycloalkyl, C 1 -C 6 -alkyl aryl, C 2 -C 6 -alkyl heteroaryl, C 3 -C 8 -alkyl cycloalkyl, C 1 -C 6 -alkyl heterocycloalkyl, C 2 -C 6 -alkenyl aryl, C 2 -C 6 -alkenyl heteroaryl, C 2 -C 6 -alkynyl aryl, and C 2 -C 6 -alkynyl heteroaryl;  
         R 3  is selected from the group consisting of C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, aryl, heteroaryl, C 3 -C 8 -cycloalkyl or heterocycloalkyl, C 1 -C 6 -alkyl aryl, C 1 -C 6 -alkyl heteroaryl, C 1 -C 3 -alkyl cycloalkyl, C 1 -C 3 -alkyl heterocycloalkyl, C 2 -C 6 -alkenyl-aryl, C 2 -C 6 -alkenyl-heteroaryl, C 2 -C 6 -alkynyl aryl C 2 -C 6 -alkynyl heteroaryl carboxy, cyano, halogen, hydroxy, C 1 -C 6 -alkoxy, nitro, acylamino, ureido, sulfonylamino, sulfanyl, and sulfonyl, and  
         R 4  is selected from the group consisting of C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, and C 2 -C 6 -alkynyl; and  
         m is an integer from 0 to 3, and  
         n is an integer from 0 to 2.  
       
     
     
         19 . A compound of the formula VIII,  
       
         
           
           
               
               
           
         
         wherein R 1  is a 1,1′-biphenyl or a tert-butyl phenyl moiety  
         R 4  is selected from the group consisting of C 1 -C 6 -alkyl. C 1 -C 6 -alkenyl, and C 2 -C 6 -alkynyl; and  
         n is an integer from 0 to 2.  
       
     
     
         20 . A method of preparing the compound of formula (Ia) according to  claim 6 , comprising: 
 deprotecting a first compound represented by formula Va in the presence of a base and a second compound represented by formula VI to obtain the compound represented by formula Ia                          wherein PG is a protecting group selected from Boc, Fmoc and Cbz.    
     
     
         21 . A method of preparing the compound represented by formula Ia according to  claim 6 , comprising: 
 peptide coupling a first compound represented by formula VIII with a second compound represented by formula IVa to obtain the compound represented by formula Ia                          
     
     
         22 . A method of treating dysmenorrhea, preterm labor, premature birth or stopping labor prior to cesarean delivery comprising 
 administering a composition comprising the compound, geometrical isomers of said compound, optically active forms of said compound, enantiomers of said compound, diastereomers of said compound, racemate forms of said compound, pharmaceutically acceptable salts of said compound and pharmaceutically active derivatives thereof as claimed in  claim 1  to a patient in need thereof.